Press Release: CaaMTech’s Psychedelic Functional Unblinding Strategy Gets Regulatory Blessing

ISSAQUAH, WA / ACCESSWIRE / November 14, 2024 / CaaMTech, Inc. is pleased to announce positive feedback from United States federal government regulators for its CT-4201 psilocin prodrug program. Amongst other topics, the regulator’s feedback validated CaaMTech’s plan for functional unblinding of its CT-4201 drug trials. This validation clears the clinical development pathway for CT-4201, a […]